1.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 months to 18 years Sponsor: Pharmaceutical / Industry Protocol IDs: CPKC412A2114, 2008-006931-11, NCT00866281
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: NCI Protocol IDs: CASE1908, NCI-2009-01285, NCT01093573
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0374, NCT01202877
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: AMLSG 16-10, 2011-003168-63, NCT01477606
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: TUD-MIDOKI-052, 2011-002567-17, NCT01830361
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 60 and over Sponsor: NCI, Other Protocol IDs: HEMAML0022, NCI-2013-00868, NCT01846624
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-09111, NCI-2010-01335, NCT01174888
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-457, NCT01282502
|